Carina Leys

USPTO Granted Patents = 9 (Patent Applications = 4)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 6)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Stabroek, BE (2012 - 2014)
Beerse, BE (2017)

Company Filing History:

6 out of 2,076

Janssen Pharmaceutica Nv

patents

2 out of 66

Tibotec Pharmaceuticals Ltd.

Years Active: 2012-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12269813 - Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate (2025-04-08),

2. 9642799 - Crystalline 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-0X0-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide (2017-05-09),

3. 8853406 - Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 (2014-10-07),

4. 8759519 - Mono-hydrochloric salts of an inhibitor of histone deacetylase (2014-06-24),

5. 8716282 - Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors (2014-05-06),

6. 8629144 - Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline (2014-01-14),

7. 8546428 - Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol (2013-10-01),

8. 8426434 - Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile (2013-04-23),

9. 8143402 - Polymorphic forms of a macrocyclic inhibitor of HCV (2012-03-27),

Title: Carina Leys: Pioneering Innovations in Pharmaceutical Chemistry

Introduction

Carina Leys, an accomplished inventor based in Stabroek, Belgium, has made significant contributions to the field of pharmaceutical chemistry. With a total of eight patents to her name, she has been at the forefront of developing innovative compounds that aim to address critical health issues.

Latest Patents

Among her latest inventions are two noteworthy patents. The first is for a crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate. This invention relates to a crystalline form and processes for its preparation, which hold promise in treating MALT-1 related diseases. The second patent involves substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53. This patent provides breakthrough compounds that can inhibit the p53-MDM2 interaction, along with pharmaceutical compositions featuring these compounds.

Career Highlights

Throughout her career, Carina Leys has collaborated with reputable companies such as Janssen Pharmaceutica NV and Tibotec Pharmaceuticals Ltd. Her work in these organizations has paved the way for groundbreaking advancements in the treatment of various diseases. Her dedication to innovation and excellence has established her as a leading figure within her industry.

Collaborations

Carina has also effectively collaborated with notable colleagues in her field, including Sigrid Carl Maria Stokbroekx and Johan Erwin Edmond Weerts. These partnerships have helped to cultivate a creative environment that fosters groundbreaking discoveries and the progression of pharmaceutical innovations.

Conclusion

Carina Leys stands out as a prominent inventor whose work has had a lasting impact on pharmaceutical science. Her patented inventions not only illustrate her exceptional skills in innovation but also contribute significantly to advancements in medical treatments. As she continues to push the boundaries of research and development, Carina Leys remains a vital player in the world of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.